Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
In the 2020 February 25 issue of Scientific Reports, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that levels of a circulating soluble immune checkpoint protein can be used as a potential marker to predict overall survival in patients with advanced HCC.
Scientists from the Cancer Science Institute of Singapore at the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR)'s Genome Institute of Singapore have discovered four potential drug compounds that target hepatocellular carcinoma, the most common type of liver cancer.
Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich and the Helmholtz Center for Infection Research in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.
Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the U.S. Food and Drug Administration, according to a City of Hope-led study.
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma compared to standard of care, showed results from a phase 3 study reported at the ESMO Asia 2019 Congress.
Liver cancer affects hundreds of thousands of people annually, and there are few viable therapies for the advanced stages of its most common form--hepatocellular carcinoma.
In an article published today by SAGE Publishing, investigators from The Nagourney Cancer Institute and The Albert Einstein Israelite Hospital in São Paulo, Brazil, announced a new approach to identifying effective treatments for patients with advanced metastatic cancers. A drug commonly used to treat kidney and liver cancer was discovered effective for breast cancer, which may open new drug therapies to patients regardless of tumor type.
In recent years, the number of targeted cancer drugs has continued to rise. However, conventional chemotherapeutic agents still play an important role in cancer treatment.
In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.
EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.
Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.
Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.
Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.